An interventional study of Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician. in Gestational Diabetes Mellitus, sponsored by Wolfson Medical Center. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Wolfson Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diabetes, Gestational with a site in Israel — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Israel.
Among the 25 studies in Diabetes, Gestational with a site in Israel, this one is the 15th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 25th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →6 of the 25 studies in Diabetes, Gestational with a site in Israel are open now. Recruiting first, the newest first:
Hadassah Medical Organization · Sites in Israel
Ages 18–45 · Women only
The Baruch Padeh Medical Center, Poriya · Sites in Israel
Ages 18+ · Women only
Hadassah Medical Organization · Sites in Israel
Ages 18–50 · Women only
HaEmek Medical Center, Israel · Sites in Israel
Ages 18–60 · Women only · Healthy volunteers
Smartest Technologies · Sites in Israel
Ages 18–80 · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 51 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 142 across the 15 interventional studies, 150 across the 9 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Wolfson Medical Center is the lead sponsor of 118 studies on the registry; 17 are open to participants now.
Wolfson Medical Center has 2 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06355154Hadassah Medical OrganizationEffects of Moderate Carbohydrate Consumption on Metabolic and Obstetric Outcomes in Pregnant Women With Insulin-treated Diabetes- A Randomized Controlled Trial | 2027-05-01 |
| NCT07158970Wolfson Medical CenterHome-Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus (GDM) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Diabetes, Gestational with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the impact of incorporating home-ultrasound (home-US) devices into telemedicine care for patients with gestational diabetes mellitus (GDM). The study will compare satisfaction, clinical outcomes, and healthcare costs between standard high-risk pregnancy care and care augmented by home-US.
Gestational diabetes mellitus (GDM) requires frequent follow-up to monitor maternal and fetal well-being. While telemedicine improves access and patient satisfaction, it lacks a fetal assessment component. This single-center randomized controlled trial evaluates the integration of home ultrasound (home-US) into telemedicine care for women with GDM.
Participants will be randomized to standard care or an intervention group receiving alternating in-person and telemedicine visits with physician-guided home-US using the Pulsenmore device. The primary outcome is patient satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at term. Secondary outcomes include glycemic control, maternal and neonatal outcomes, healthcare utilization, visit duration, and follow-up costs.
The study will enroll 90 women, aged 18-51, with singleton pregnancies and GDM. The study is conducted at the Edith Wolfson Medical Center in Israel over a one-year period. The home-US device is approved for obstetric use and will be used under real-time physician supervision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Home Ultrasound Monitoring
Device: Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.
Standard high-risk follow up in clinic
Standard care
Patient satisfaction
Assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ). It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.
Time frame: at 37-39 weeks gestation
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score
Difference in patient satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) between early pregnancy (after first visit) and late pregnancy (37-39 weeks gestation). It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.
Time frame: From enrollment (~24-28 weeks) to 37-39 weeks gestation.
Glycemic Control
Assessment of maternal glycemic control based on percent of abnormal glucose values during follow-up (via glucose log or continuous glucose monitoring where available), as recorded by treating physician.
Time frame: From enrollment to delivery.
Clinician Satisfaction
Clinician satisfaction will be assessed using a structured questionnaire developed for this study. Physicians will rate various aspects of the telemedicine or in-person follow-up experience, including: Ease of use Clinical value Workflow and efficiency Communication and patient engagement Technical issues and support Each domain will be rated on a 10-point numeric rating scale (0-10), where: 0 = Not satisfied at all 10 = Extremely satisfied Higher scores indicate greater satisfaction.
Time frame: At the end of study participation for each patient (between 37-39 weeks gestation).
Mode of Delivery
Evaluation of mode of delivery (vaginal, cesarean)
Time frame: At time of delivery.
Neonatal birth-weight
Birth weight
Time frame: At time of delivery
Estimated Patient Follow-up Costs
Estimated costs incurred by patients for follow-up (including travel, parking, time off work), collected via structured questionnaire.
Time frame: At 37-39 weeks gestation.
Estimated Institutional Follow-up Costs
Estimated resource and time costs for the healthcare system based on visit type (in-person vs. telemedicine), calculated per patient.
Time frame: From enrollment to delivery.
Visit Duration
Duration of each visit, separately recorded for patient time and physician Duration of each clinical visit will be recorded in minutes for both the patient and the physician. This includes both in-person and telemedicine encounters. Separate timing will be documented for: Patient time (including waiting and consultation) Physician time (active interaction and documentation) These data will be used to compare time efficiency between the two care models.
Time frame: Through study completion, an average of 1 year (from enrollment to delivery for each participant)
Unscheduled Emergency Department Visits
Number and reason for unscheduled emergency room visits related to pregnancy or GDM during the study period.
Time frame: From enrollment to 6 weeks postpartum, confirmed by patient interview and EMR.
Gestational age at birth
Gestational age at birth
Time frame: collected after birth from data system
Number of Neonates Admitted to the Neonatal Intensive Care Unit (NICU)
The number of neonates requiring admission to the neonatal intensive care unit (NICU) following delivery will be recorded and reported. This will be used as an indicator of neonatal morbidity.
Time frame: Within the first 28 days of life
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 17 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.